Lyell Immunopharma Ownership | Who Owns Lyell Immunopharma?


OverviewForecastRevenueFinancialsChart

Lyell Immunopharma Ownership Summary


Lyell Immunopharma is owned by 7.98% institutional investors, 18.72% insiders, and 73.30% retail investors. Arch venture management is the largest institutional shareholder, holding 18.65% of LYEL shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.44% of its assets in Lyell Immunopharma shares.

LYEL Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockLyell Immunopharma7.98%18.72%73.30%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Arch venture management2.76M18.65%$44.81M
Foresite capital management iv800.40K5.41%$13.00M
Blackrock13.50M5.31%$19.57M
Vanguard group779.00K5.27%$12.65M
Almitas capital577.81K3.91%$9.38M
Foresite capital management v477.08K3.23%$7.75M
Venbio partners473.48K3.20%$7.69M
Wuxi apptec7.68M3.02%$11.14M
Alphabet293.26K1.98%$4.76M
Blackrock funding, inc. /de176.81K1.20%$2.87M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Wuxi apptec7.68M47.74%$11.14M
Arch venture management2.76M9.10%$44.81M
Foresite capital management v477.08K7.12%$7.75M
Foresite capital management iv800.40K7.12%$13.00M
Venbio partners473.48K4.36%$7.69M
Almitas capital577.81K2.15%$9.38M
Takeda pharmaceutical41.16K1.86%$363.91K
Decheng capital595.47K1.33%$5.26M
Mic capital management uk llp87.03K0.28%$1.41M
Alphabet293.26K0.20%$4.76M

Top Buyers

HolderShares% AssetsChange
Arch venture management2.76M9.10%938.44K
D. e. shaw966.26K0.00%493.64K
Wellington management group llp367.68K0.00%367.68K
Vanguard group779.00K0.00%336.38K
Millennium management957.51K0.00%247.44K

Top Sellers

HolderShares% AssetsChange
Decheng capital595.47K1.33%-11.31M
Opaleye management---1.40M
Balyasny asset management---1.20M
Mwg management---1.01M
Invenomic capital management lp---871.52K

New Positions

HolderShares% AssetsChangeValue
Wellington management group llp367.68K0.00%367.68K$533.13K
Trexquant investment lp10.28K0.00%10.28K$166.87K
Rangeley capital10.00K0.14%10.00K$162.40K
Royal bank of canada4.19K-4.19K$68.00K
Macquarie group505.00-505.00$732.00

Sold Out

HolderChange
Eversource wealth advisors-1.00
Pnc financial services group-4.00
True wealth design-23.00
Nelson, van denburg & campbell wealth management group-34.00
Rothschild investment-50.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202515-78.26%1,180,540-87.25%70.20%6-50.00%4-92.86%
Jun 30, 202568-39.82%9,256,423-93.92%62939.01%12-68.42%5552.78%
Mar 31, 20251128.74%152,309,7191.35%511.50%38-26.92%3748.00%
Dec 31, 202497-17.09%146,305,21013.92%572.27%47-6.00%24-22.58%
Sep 30, 20241170.86%128,424,945-3.67%501.82%514.08%31-27.91%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv276.12K1.44%-6.10K
iShares Russell 2000 ETF4.13M1.39%-
T. Rowe Price Health Sciences212.18K1.10%-2.38K
Biotech Growth Ord2.88M0.99%-
Vanguard Small Cap Index2.24M0.87%5.37K
iShares Russell 2000 Value ETF1.47M0.49%-
Vanguard Small Cap Growth Index Inv1.25M0.49%-5.54K
Vanguard Institutional Extnd Mkt Idx Tr91.69K0.48%-37.12K
Fidelity Small Cap Index1.63M0.44%-
State St Russell Sm/Mid Cp® Indx NL Cl C1.18M0.40%-

Recent Insider Transactions


DateNameRoleActivityValue
Nov 10, 2025Seely Lynn President and CEOSell$6.64K
Nov 10, 2025Bulis Veronica Sanchez VP, Corporate ControllerSell$3.85K
Nov 10, 2025Lee Gary K. Chief Scientific OfficerSell$2.23K
Nov 10, 2025Hill Stephen J. Chief Operating OfficerSell$1.53K
Aug 21, 2025Seely Lynn President and CEOSell$76.52K

Insider Transactions Trends


DateBuySell
2025 Q4-4
2025 Q3-12
2025 Q2--
2025 Q15-
2024 Q4--

LYEL Ownership FAQ


Who Owns Lyell Immunopharma?

Lyell Immunopharma shareholders are primarily institutional investors at 7.98%, followed by 18.72% insiders and 73.30% retail investors. The average institutional ownership in Lyell Immunopharma's industry, Biotech Stocks , is 45.22%, which Lyell Immunopharma falls below.

Who owns the most shares of Lyell Immunopharma?

Lyell Immunopharma’s largest shareholders are Arch venture management (2.76M shares, 18.65%), Foresite capital management iv (800.4K shares, 5.41%), and Blackrock (13.5M shares, 5.31%). Together, they hold 29.37% of Lyell Immunopharma’s total shares outstanding.

Does Blackrock own Lyell Immunopharma?

Yes, BlackRock owns 5.31% of Lyell Immunopharma, totaling 13.5M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 19.57M$. In the last quarter, BlackRock decreased its holdings by -397K shares, a -2.86% change.

Who is Lyell Immunopharma’s biggest shareholder by percentage of total assets invested?

Wuxi apptec is Lyell Immunopharma’s biggest shareholder by percentage of total assets invested, with 47.74% of its assets in 7.68M Lyell Immunopharma shares, valued at 11.14M$.

Who is the top mutual fund holder of Lyell Immunopharma shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Lyell Immunopharma shares, with 1.44% of its total shares outstanding invested in 276.12K Lyell Immunopharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools